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ABSTRACT: In the past two decades, recreational use of ecstasy has
become a growing concern in the United States, although most studies
assessing ecstasy use have focused on white, middle-class adolescents who
use ecstasy during raves and in clubs. We assessed the prevalence of
recent ecstasy use among predominantly minority heroin, cocaine, and
crack users in New York City and the association between ecstasy and
sexual risk above and beyond that of the other drugs. Between 2002
and 2004, injection and non-injection heroin, crack and cocaine users
(N = 534) completed a risk behavior questionnaire that included items
on ecstasy use. Logistic regression was used to investigate the relation
between current ecstasy use and sexual behaviors. Of 534 illicit drug
users, 69.7% were aged 25 years or older, 65.2% were Hispanic, 27.9%
Black and 77.4% male; 36.7% were injectors. 17.2% of respondents
reported recent (last six months) ecstasy use. In a multivariable logistic
regression model, current ecstasy use was associated both with initiating
sex before age 14 (adjusted odds ratio (AOR) = 1.51) and having two or
more partners in the past two months (AOR = 1.86) after adjusting for
age at study entry, current cocaine and marijuana use and being an
injection drug user. This study suggests that ecstasy use may be more
prevalent among urban drug users. Ecstasy use in urban settings, beyond
clubs and raves, should continue to be monitored.
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INTRODUCTION
In the past two decades, recreational use of 3,4-methylenedioxy-
amphetamine (MDMA or ‘‘ecstasy’’) has become a growing concern in the
United States. A derivative of amphetamines, ecstasy users report a sense of
euphoria and increased wakefulness, energy, excitement, and sexual plea-
sure.1,2 In 2000, the Monitoring the Future (MTF) study found that 11% of
12th graders had used the drug at some point in their lives.3 Between 1997
and 1998, the prevalence of past-year ecstasy use among college students
rose from 2.8% to 4.7% in a national sample of college students.4 A sepa-
rate study of undergraduates in New England documented rates of lifetime
ecstasy use increase from 4.1% in 1989 to 10.1% in 1998.5 Although
emergency department mentions of MDMA declined from 5542 in 2001 to
4026 in 2002,6 it is still too early to tell if this decline represents a trend.
Currently available data suggests that ecstasy use in the United States
is relatively common7,8 and national surveillance data have suggested that
ecstasy use is declining among adolescents.9 However, these observations
have been made from studies conducted among predominantly white pop-
ulations, including national surveillance studies (e.g., MTF, National
Household Survey on Drug Abuse), rave or circuit party attendees10–12 and
men who have sex with men.10–13 Previously reported to be used by rave (all
night dance party) and night club attendees as a ‘‘club drug,’’ ethnographic
reports from the Community Epidemiology Working Group (CEWG)14 and
a random digit dial phone survey of the general population in Chicago15
suggest that ecstasy has moved beyond the clubs and into other social venues.
Though ecstasy has been linked to isolated cases of heat stroke, hyponatre-
mia, kidney failure, rhabdomyolysis,16 hepatotoxicity17 and cardiovascular
toxicity,18,19 a key public health concern about ecstasy use is the resulting
impaired judgment of its users that may lead to behaviors that put individ-
uals at risk for HIV and other sexually transmitted diseases.
In a study of college students, Boyd et al.20 found that, compared to
participants who reported no sexual partners, those with five or more
partners were 4.6 times more likely to have used ecstasy in the past month,
5.4 times more likely to have used in the past year, and 9.3 times more
likely to have ever used. However, the models did not control for other
drugs used, an important limitation given that those reporting use of
ecstasy users often do so with other drugs.21
The relationship between ecstasy use and sexual risk has been
documented among men who have sex with men (MSM) and circuit party
attendees.22 In a study of MSM nightclub attendees, ecstasy was associated
with more incidents of unprotected anal sex, even after controlling for
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ethnicity, age, and other forms of drug use.13 A later study by the same
author found that young ecstasy users were also more likely to frequent
bars, clubs, and bathhouses, to have more male partners, and to have more
one night stands with men.23 In young MSMs, ecstasy use was associated
with unprotected anal intercourse24, and Mattison et al.10 found frequent,
but not lifetime use, of ecstasy to be associated with unprotected anal
sex.
Currently, data are sparse about sexual risk and ecstasy use among the
urban poor, a group that have been disproportionately affected by HIV and
sexually transmitted diseases.25–27 In a telephone survey of 627 randomly
selected Chicago residents, those of lower socioeconomic background and
minorities were less likely to use ‘‘club drugs’’ (defined by the National
Institute on Drug Abuse as MDMA, GHB, ketamine, rohypnol, metham-
phetamine, LSD), but this was not disaggregated by drug.15 However, cities
such as Atlanta, Baltimore, Dallas, and New York have reported an increases
in availability of ecstasy in their minority communities.14,28 To date, quanti-
tative data on ecstasy use in inner-city, predominantly minority communities
are limited. To examine this issue, we assumed that sampling a subset that are
known to use other illicit non-injection drugs would provide an efficient
means to detect the presence of club drug use and possible associations.
While detection in this subset cannot be generalized to the entire minority
inner city community (especially if ecstasy and these other drugs do not
overlap), this approach can provide a window into a population segment that
otherwise might be at higher risk for sexual risk. Therefore the purpose of
this study was to determine the prevalence of recent ecstasy use among her-
oin, cocaine and crack users in New York City and assess the association of
ecstasy and sexual risk above and beyond that of the other drugs.
METHODS
Between October 2002 and February 2004, we interviewed sub-
stance users from two ongoing studies of NIDUs and IDUs29,30 using street
outreach techniques. Areas of high drug traffic were identified in target
communities. Working in pairs, outreach workers concentrated their time
in these key locations at different times of the day and created rapport with
potential study participants and the community at large. Outreach workers
engaged drug users in conversations about ongoing research at the
research storefronts and mobile van in the communities where drugs were
bought and/or used. At each location, outreach workers explained the
purpose of the study to potential participants. Individuals interested in
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participating in a study were then given an appointment at a data collection
site, either at one of two stationary storefronts in Central Harlem (Man-
hattan) and the South Bronx or at a mobile van that parked in Brooklyn,
the Lower East Side of Manhattan and Queens, all in New York City.
Potential participants were screened to see if they were eligible for
one of two studies. The Hepatitis C Study was a study of IDUs designed to
examine correlates and predictors of hepatitis C infection and therefore
targeted young, recently initiated IDUs at risk for HCV infection. Partici-
pants were eligible for the injector part of the study if they were age 15 to
40 years and reported injecting drug use of heroin or cocaine at least once
in the last two months but for no longer than 5 years. The Harlem Out-
reach, Prevention and Education (HOPE) Study was a study of NIDUs
aimed at investigating correlates and predictors of transition to injection
drug use, and therefore recruited young NIDUs. Participants were eligible
for the non-injector part of the study if they were age 15 to 40 years and
reported non-injecting drug use of heroin or cocaine at least once per week
in the last two months but for no longer than 10 years, and no history of
injecting drug use. Participants were reimbursed $20 for their participa-
tion. The study was approved by the institutional review board of the New
York Academy of Medicine.
Data Collection
Trained interviewers administered to eligible and consenting indi-
viduals a standardized, detailed risk behavior questionnaire that included
items for sociodemographic characteristics, type and frequency of drug use,
sexual behaviors and sexual partnerships. Questionnaires were adminis-
tered in both English and Spanish.
Sociodemographic characteristics considered included age, race,
gender, education, recent homelessness, and main income source (e.g.,
employed, illegal, or public assistance). Drug use variables were ascertained
and injection was confirmed using inspection for track marks during
venipuncture. Recent ecstasy use was defined as any use in the last six
months. Sexual partnerships were defined either by the sex partner’s
behavior (i.e. crack, use, injection drug use, etc.) or by their infection status
(i.e. HIV or HCV positive, etc.).
Statistical Methods
We compared current (within the last six months) ecstasy users to
non-current users in terms of sociodemographic characteristics, drug use
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(including types, frequency and route of administration), sexual behaviors,
and sexual partnerships. Polysubstance use was defined as the mean
number of drugs used out of a list of 13, which included heroin, crack,
cocaine, marijuana, LSD, PCP, ecstasy, methamphetamine, amphetamine,
ketamine, tranquilizers, inhalants, and GHB. Bivariate analyses were con-
ducted to examine demographic and risk behavior variables by current
ecstasy use using v2 statistics for categorical variables and t tests for con-
tinuous variables. Variables that were significantly associated with ecstasy
use (p < 0.10) in the bivariate analysis were entered into a final multivari-
able logistic model and only those that were significant at p < 0.05 were
retained in the model. We used generalized estimating equations (GEE) to
control for clustering effects at our three recruitment sites. All analyses
were conducted using SAS version 8.02 (SAS Institute, Cary, North Caro-
lina).
RESULTS
In our sample of 534 drug users, the proportion reporting recent
use (last six months) of ecstasy was 17.2%. Table 1 presents the demo-
graphic characteristics for the total sample and by current use of ecstasy
(yes, no). Overall, the sample was predominantly male (77.4%) and largely
composed of racial/ethnic minorities, with 65.2% identifying as Hispanic
and 27.9% as Black. The sample was predominantly heterosexual (87.1%).
Over half (56.9%) had less than a high school education, and 61.7% had
been homeless at some point in the 6 months prior to their participation.
Compared to current non-users, current users were significantly more likely
to be under 25 years of age (p < 0.01). Hispanics were somewhat more
likely than blacks or whites to have used ecstasy, but these results were not
statistically significant (p = 0.21).
Table 2 shows the drug-using and sexual characteristics of the
sample. Current drug use was defined as use of the drug via any route of
administration in the last 6 months. In terms of legal drug use, 91.2% had
used cigarettes on a daily basis and 16.9% has used alcohol on a daily basis.
Turning to illegal drug use, 66.9% had used heroin, 70.6% used cocaine,
50.2% used crack, and 68.5% used marijuana over the past 6 months. Over
one-third (37%) reported lifetime injection drug use. The mean number of
drugs used over the last 6 months was 2.1 (Standard Deviation (SD) = 1)
out of a possible 13. In bivariate analysis, current ecstasy use was associated
with both current cocaine and current marijuana use (p < 0.0001), but not
with crack or heroin (p = 0.85, 0.71 respectively).
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TABLE 1
Demographic Characteristics of 534 Illicit Drug Users in New York City,
by Current (Past Six Month) Ecstasy Use
Characteristics
Total N = 534
N (%)
Ecstasy (+)
n = 92 (17.2)
Ecstasy ())
n = 442 (82.8) p-value
Sex
Male 408 (77.4) 75 (18.4) 333 (81.6) 0.09
Female 119 (22.6) 14 (11.8) 105 (88.2)
Race
Hispanic 348 (65.2) 67 (19.3) 281 (80.7) 0.21
Black 149 (27.9) 21 (14.1) 128 (85.9)
White 37 (6.9) 4 (10.8) 33 (89.2)
Age
<25 162 (30.3) 50 (30.9) 112 (69.1) <0.01
‡25 372 (69.7) 42 (11.3) 330 (88.7)
Sexual identity
Heterosexual 453 (87.1) 78 (17.2) 375 (82.8) 0.79
Homosexual/Lesbian 28 (5.4) 4 (14.3) 24 (85.7)
Bisexual 39 (7.5) 8 (20.5) 31 (79.5)
Education
<High school 303 (56.9) 59 (19.5) 244 (80.5) 0.12
‡Highschool/GED 230 (43.2) 33 (14.4) 197 (85.7)
Homelessness in last 6 months
No 204 (38.3) 30 (14.7) 174 (85.3) 0.21
Yes 329 (61.7) 62 (18.8) 267 (81.2)
Employment type
Employed 41 (7.8) 5 (12.2) 36 (87.8) 0.02
Illegal 246 (46.7) 54 (22.0) 192 (78.1)
Public assistance 117 (22.2) 11 (9.4) 106 (90.6)
Others 123 (23.3) 22 (17.9) 101 (82.1)
Site
Bronx 221 (41.4) 33 (14.9) 188 (85.1) 0.03
Harlem 182 (34.1) 42 (23.1) 140 (76.9)
Van 131 (24.5) 17 (13.0) 114 (87.0)
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TABLE 2
Drug Use and Sexual Risk Among Illicit Drug Users in New York City, by
Current (Past Six Month) Ecstasy Use
Total N = 534
N (%)
Ecstasy (+)
N = 92 (17.2)
Ecstasy ())
N = 442 (82.8) p-value
Current cigarette use
None 10 (2.1) 0 (0.0) 10 (100.0) 0.12
<Daily 32 (6.7) 3 (9.4) 29 (90.6)
Daily 436 (91.2) 86 (19.7) 350 (80.3)
Current alcohol
None 108 (20.2) 11 (10.2) 97 (89.8) 0.09
<Daily 336 (62.9) 64 (19.1) 272 (80.9)
Daily 90 (16.9) 17 (18.9) 73 (81.1)
Current marijuana use
No 168 (31.5) 6 (3.6) 162 (96.4) <0.01
Yes 366 (68.5) 86 (23.5) 280 (76.4)
Current heroin use
No 177 (33.2) 32 (18.08) 145 (81.9) 0.71
Yes 357 (66.9) 60 (16.81) 297 (83.2)
Current cocaine use
No 157 (29.4) 7 (4.5) 150 (95.5) <0.01
Yes 377 (70.6) 85 (22.6) 292 (77.5)
Current Crack use
No 266 (49.8) 45 (16.9) 221 (83.1) 0.85
Yes 268 (50.2) 47 (17.5) 221 (82.5)
Polysubstance
use in last 6 months*
2.1 (1.0) 2.3 (1.0) 2.0 (1.0) <0.01
IDU
No 338 (63.3) 66 (71.7) 272 (61.5) 0.06
Yes 196 (36.7) 26 (28.3) 170 (38.5)
Sexual behaviors
Mean age at first
intercourse




2.8 (5.2) 3.5 (4.4) 2.7 (5.4) 0.12
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TABLE 2 (Continued)
Total N = 534
N(%)
Ecstasy (+)
N = 92 (17.2)
Ecstasy ())
N = 442 (82.8) p-value
Traded sex for money or drugs
No 462 (86.5) 74 (16.0) 388 (84.0) 0.06
Yes 72 (13.5) 18 (25.0) 54 (75.0)
Sex before getting high
No 164 (31.1) 17 (10.4) 147 (89.6) <0.01
Yes 364 (68.9) 73 (20.1) 291 (80.0)
Sex after getting high
No 96 (18.1) 7 (7.3) 89 (92.7) <0.01
Yes 435 (81.9) 85 (19.5) 350 (80.5)
Partners who smoke crack
No 388 (73.1) 68 (17.5) 320 (82.5) 0.56
Yes 143 (36.9) 22 (15.4) 121 (84.6)
Partners who use heroin
No 408 (76.4) 72 (17.7) 336 (82.4) 0.64
Yes 126 (23.6) 20 (15.9) 106 (84.1)
Partners who inject
No 449 (87.0) 75 (16.7) 374 (83.3) 0.81
Yes 67 (13.0) 12 (17.9) 55 (82.1)
Partners who snort/sniff cocaine
No 384 (71.9) 54 (14.1) 330 (85.9) <0.01
Yes 150 (28.1) 38 (25.3) 112 (74.7)
Partners who are hepatitis positive
No 505 (94.8) 91 (18.0) 414 (82.0) 0.08
Yes 28 (5.3) 1 (3.6) 27 (96.4)
Partners who are HIV/AIDS infected
No 512 (96.2) 89 (17.4) 423 (82.6) 0.78
Yes 20 (3.8) 3 (15.0) 17 (85.0)
*Mean number of drugs used out of list of 13: heroin, crack, cocaine, marijuana, LSD, PCP,
ecstasy, methamphetamine, amphetamine, ketamine, tranquilizers, inhalants, GHB.
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In terms of sexual behavior, the mean number of partners in the
last 2 months was 2.8 (SD = 5.2), and the mean age at first sexual inter-
course was 14.2 (SD = 2.5). The majority of participants reported having
sex before and after getting high (69% and 82%, respectively). Overall,
13.5% had traded sex for money or drugs in the prior two months, and only
20 people (3.8%) reported having sex with an HIV-seropositive partner. In
the bivariate analysis, current ecstasy use was associated with having sex
before getting high, having sex after getting high, and having partners who
sniffed or snorted cocaine (p < 0.01).
In the final model (Table 3), current ecstasy use associated both
with initiating sex before age 14 (adjusted odds ratio (AOR): 1.51) and with
TABLE 3





OR 95% CI p-value
Age
>25 1.00 1.00 <0.01
£ 25 3.51 (2.21, 5.58) 3.61 (3.48, 3.75)
Current cocaine use
No 1.00 1.00 <0.01
Yes 6.24 (2.82, 13.82) 3.58 (2.07, 6.20)
Current marijuana use
No 1.00 1.00 <0.01
Yes 8.29 (3.54, 19.40) 5.25 (3.53, 7.82)
Injection drug user
No 1.00 1.00 0.01
Yes 0.67 (0.42, 1.09) 0.46 (0.25, 0.83)
Age at sexual initiation
‡14 1.00 1.00 <0.01
<14 1.76 (1.11, 2.78) 1.51 (1.36, 1.68)
Number of sex partners
<2 1.00 1.00 <0.01
‡2 2.42 (1.52, 3.86) 1.86 (1.40, 2.45)
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having two or more partners in the past two months (OR = 1.86) after
adjusting for age at study entry, current cocaine and marijuana use and
being an injection drug user. In terms of goodness-of-fit, the Pearson chi-
square value was 1.096 indicating that the model fits the empirical data
well.
DISCUSSION
We showed that use of ecstasy is not uncommon among those
reporting other illicit drugs within disadvantaged communities in New York
and that ecstasy use is independently associated with greater levels of sexual
risk behaviors. In particular, ecstasy users were more likely than their peers
to have multiple sexual partners. Multiple partnerships, particularly con-
current ones, have been linked to greater sexual risk and increased HIV
transmission.31 Furthermore, having sex before the age of fourteen was
more frequent among those who reported recent ecstasy use. Although not
a direct marker for HIV risk, early sexual debut has been associated with
irregular condom use, and among females, with sexually transmitted
infections.32
In the absence of published studies for comparison on ecstasy use
and sexual risk among heterosexual drug users, we observed a concordance
with the literature on ecstasy use and sexual risk in other populations. Our
findings are consistent with those of Boyd et al.20 who studied under-
graduates at a Midwestern university and found that ecstasy use was asso-
ciated with having multiple sex partners. Similarly, Klitzman23 also found
that ecstasy use was associated with having more partners in their sample of
MSM.
We observed no significant association between current ecstasy use
and race or ethnicity. This differs from population-based studies like MTF31
or Fendrich and colleagues’ study of adults in Chicago15 which both noted
that whites were more likely than other groups to report ecstasy use. This
discrepancy may be due to the small number of whites in our study (6.9%)
and to our focus on characteristics of a sample drawn from the inner city
drug-using community. In either case, the relatively high rates of recent
ecstasy use among Hispanics and blacks suggest that, at least among this
population, ecstasy is not an exclusively ‘‘white suburban’’ phenomenon.
Several study limitations should be noted. Although we observed an
association between ecstasy and having more sex partners, the cross-
sectional designed used here cannot distinguish whether ecstasy increases
partnering or whether persons predisposed to multiple partners are also
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more likely to use ecstasy, i.e., this association might simply indicate a
predisposition to risk caused by some other underlying, unmeasured factor.
Selection bias is also a potential limitation. Given the substance-use criteria
for participation, our findings regarding ecstasy use cannot be generalized
to urban minority communities or to the general population. Even within
the substance-using population, the strict selection criteria excluded older
drug users, long-term IDUs, and former IDUs and the street-based
recruitment strategy may have missed individuals that did not participate in
the drug economy at the times during which we recruited. In addition,
because we relied on self-reported ecstasy use, we cannot know for certain
that the ‘‘ecstasy’’ reportedly used was truly ecstasy. The purity of tablets
sold as ‘‘ecstasy’’ varies by country and time period, but a recent review
suggested that the purity of these tablets has risen dramatically since the
mid 1990s, and has approached 100% in several of the most recent stud-
ies.34
This study was a post hoc analysis of data collected for the purpose
of examining HCV and transition to injection drug use among injection
and non-injection drug users. Thus, we were not able to assess other risk
factors hypothesized to be associated with ecstasy use such as familial fac-
tors, social networks and environmental factors. Finally, questions about
sexual behaviors are sensitive and rates may be under or overestimated.
However, we do not expect that the reporting of sexual behaviors would be
differential between ecstasy users and non-users.
With limitations acknowledged, our study suggests a relatively
high prevalence of ecstasy use in an understudied population, and shows
an association between ecstasy use and risky sexual behavior. Ecstasy use
in urban settings, beyond clubs and raves, should continue to be mon-
itored. Further research is required to determine the directionality of
the association and the effects of ecstasy on condom usage, but our
findings, together with the other reports on the prevalence of ecstasy use
and the already-high prevalence of HIV in urban communities, hold
troubling implications for the future of the HIV epidemic in this pop-
ulation.
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